|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
Bausch + Lomb (2013)
Ortho Dermatologics (2014)
Salix Pharmaceuticals (2019)
|
|
gptkbp:ceo
|
gptkb:Joseph_C._Papa
|
|
gptkbp:focus
|
Gastroenterology
Medical devices
Pain management
Neurology
Dermatology
Eye health
Consumer health products
Therapeutics
Pharmaceutical products
Vision care
Surgical products
Aesthetic products
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:founder
|
gptkb:Bausch_&_Lomb
|
|
gptkbp:headcount
|
~21,000
|
|
gptkbp:headquarters
|
gptkb:Laval,_Quebec,_Canada
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bausch Health Companies Inc.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:market_cap
|
$8.5 billion (2021)
|
|
gptkbp:number_of_employees
|
~21,000
|
|
gptkbp:partnership
|
Various healthcare organizations
|
|
gptkbp:products
|
Prescription drugs
Over-the-counter products
|
|
gptkbp:revenue
|
$8.1 billion (2020)
|
|
gptkbp:stock_symbol
|
BHC
|
|
gptkbp:subsidiary
|
gptkb:Salix_Pharmaceuticals
gptkb:Bausch_+_Lomb
gptkb:Ortho_Dermatologics
|
|
gptkbp:traded_on
|
gptkb:NYSE
TSE
|
|
gptkbp:website
|
www.bauschhealth.com
|
|
gptkbp:bfsParent
|
gptkb:Bausch_&_Lomb_Optical_Company
gptkb:Bausch_+_Lomb_Eye_Health_Inc.
gptkb:Bausch_+_Lomb_Eye_Health_Ltd.
gptkb:Bausch_+_Lomb_Eye_Innovations_Inc.
gptkb:Bausch_+_Lomb_Eye_Innovations_Ltd.
gptkb:Bausch_+_Lomb_Eye_Products_Inc.
gptkb:Bausch_+_Lomb_Eye_Research_Inc.
gptkb:Bausch_+_Lomb_Eye_Research_Ltd.
gptkb:Bausch_+_Lomb_Eye_Services_Inc.
gptkb:Bausch_+_Lomb_Eye_Services_Ltd.
gptkb:Bausch_+_Lomb_Eye_Solutions_Ltd.
gptkb:Bausch_+_Lomb_Eye_Technologies_Inc.
gptkb:Bausch_+_Lomb_Eye_Technologies_Ltd.
gptkb:Valeant_Pharmaceuticals
gptkb:Bausch_+_Lomb_Canada
|
|
gptkbp:bfsLayer
|
6
|